Revolutionizing Disease Understanding with Depixus’ Ignite Award-Winning MAGNA One Technology

Depixus receives the Ignite Award at SLAS2024 for its MAGNA™ technology

Depixus, an intereactomics pioneer, has been awarded the prestigious Society for Laboratory Automation and Screening (SLAS) Ignite Award at their annual International Conference and Exhibition in Boston, MA. The award was presented to the company for their groundbreaking MAGNA™ technology.

The Ignite Award is given to companies that are revolutionizing the life sciences with their innovative technologies. Depixus was one of just 16 companies selected to participate in the SLAS2024 Innovation AveNEW program, a dedicated area for start-ups and emerging companies within the conference. From these 16 companies, the top eight were chosen as finalists for the Ignite Award.

MAGNA One is based on magnetic force spectroscopy and enables high-throughput analysis of dynamic biomolecular interactions. This technology provides real-time measurements from thousands of individual molecules simultaneously, making it particularly useful for exploring challenging targets such as RNA and protein-protein interactions. It offers valuable insights into disease mechanisms and accelerates the development of novel therapeutics.

Depixus CEO Gordon Hamilton expressed his excitement about winning the Ignite Award, emphasizing the company’s innovative technology and its potential to impact the understanding and treatment of diseases where new treatments are urgently needed. Chief Commercial Officer Steve Klose added that this timing coincides with the launch of their technology access program and commercial rollout of MAGNA One, marking a significant moment for Depixus.

For more information on Depixus or MAGNA One, visit depixus.com or contact Steve Klose at steve.klose@depixus.com

Leave a Reply